Lyell Immunopharma (LYEL) Shares Outstanding (Weighted Average) (2019 - 2026)

Lyell Immunopharma's Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $21.9 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 48.26% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at $21.9 million (up 48.26% YoY), while the FY2025 annual figure was $17.1 million, up 30.74% from the prior year.
• Shares Outstanding (Weighted Average) came in at $21.9 million for Q1 2026 at Lyell Immunopharma, up from $17.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $254.3 million in Q1 2024 to a low of $12.5 million in Q4 2023.
• A 5-year average of $125.1 million and a median of $21.9 million in 2026 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) soared 1313.72% in 2022 and tumbled 94.92% in 2023, its largest moves.
• Lyell Immunopharma's Shares Outstanding (Weighted Average) stood at $247.1 million in 2022, then sank by 94.92% to $12.5 million in 2023, then advanced by 4.18% to $13.1 million in 2024, then surged by 30.74% to $17.1 million in 2025, then increased by 27.98% to $21.9 million in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $21.9 million, $17.1 million, and $16.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison